Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Phase II Study Of Everolimus Plus Cisplatin In Triple Negative Breast Cancer Patients With Residual Disease After Standard Chemotherapy

NCT01931163 is registered in ClinicalTrials.gov with Jenny C. Chang, MD as lead sponsor.

NCT NCT01931163
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01931163 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Phase II Study Of Everolimus Plus Cisplatin In Triple Negative Breast Cancer Patients With Residual Disease After Standard Chemotherapy
Lead sponsor
Jenny C. Chang, MD
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2013
Completion date
January 31, 2019
Enrollment
24 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, triple negative breast cancer